Pharmacogenomic biomarker discovery

Pharmacogenomic biomarker discovery


Adverse drug reactions (ADRs) have been ranked as high as the fourth leading cause of death and present a significant healthcare burden to society. Genetic factors play a significant role in contributing towards why certain patients are at risk for developing these debilitating reactions.

We are currently applying high throughput genomic technologies, such as genome-wide association studies and next generation sequencing, to identify novel pharmacogenomic variants associated with various severe ADRs.

Current areas of interest:

  • Severe drug hypersensitivity reactions (cutaneous reactions and drug induced liver injury)
  • Toxicities related to cancer treatment (vincristine-induced neuropathy)
Galen Wright
Canada Research Chair in Neurogenomics